Meeting
2019 Genitourinary Cancers Symposium
Pembrolizumab for metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Updated analysis of KEYNOTE-199.
Authors
Emmanuel S. Antonarakis
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
Emmanuel S. Antonarakis , Jeffrey C. Goh , Marine Gross-Goupil , Ulka N. Vaishampayan , Josep M. Piulats , Ronald De Wit , Tuomo Alanko , Satoshi Fukasawa , Kenichi Tabata , Susan Feyerabend , Raanan Berger , Haiyan Wu , Jeri Kim , Christian Heinrich Poehlein , Johann S. De Bono
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT02787005
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 216)
DOI
10.1200/JCO.2019.37.7_suppl.216
Abstract #
216
Poster Bd #
J17
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Pembrolizumab (pembro) plus docetaxel and prednisone in patients (pts) with abiraterone acetate (abi) or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B efficacy, safety and, biomarker results.
First Author: Srikala S. Sridhar
Poster
2020 ASCO Virtual Scientific Program
Pembrolizumab (pembro) plus enzalutamide (enza) in patients (pts) with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort C efficacy, safety, and biomarker results.
First Author: Henry Jacob Conter
Poster
2020 Genitourinary Cancers Symposium
Update on KEYNOTE-199, cohorts 1-3: Pembrolizumab (pembro) for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC).
First Author: Emmanuel S. Antonarakis
Poster
2023 ASCO Genitourinary Cancers Symposium
Patient-reported outcomes (PROs) in KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) vs abiraterone acetate (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC).
First Author: Niven Mehra